Lincoln Pharmaceuticals liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

6.84×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
5.25×	5.25×	4.71×	4.84×	5.08×
4.53×	4.53×	3.97×	4.01×	4.11×
266	230	187	145	96.4
517	472	394	354	295

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

LINCOLN₹509.90

Lincoln Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersSIGACHI THEMISMED BAJAJHCARE AMRUTANJANJAGSNPHARM WANBURY AHCLMcap ₹1,021 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	6.84
Current Ratio	5.08	4.84	4.71	5.25	5.25
Quick Ratio	4.11	4.01	3.97	4.53	4.53
Cash, Equiv & ST Investments	96.4	144.7	187.1	230.1	265.9
Working Capital	294.9	354.5	393.7	472.0	516.5

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.